Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
acid, adrenergic, aesthetic, allergic, alpha, Amphastar, anesthesia, Annuity, Antonio, APLISOL, ascribed, Athenex, awaiting, Azar, benchmark, blood, Blueprint, bond, Bulletin, China, Chinese, clarity, clause, codified, colchicine, combat, commonplace, Conference, cybersecurity, deletion, desirable, detriment, Dohme, downgrade, draft, dysfunction, Eagle, economy, EGHI, epidemic, erectile, ERP, ertapenem, evidentiary, EVL, excessive, Exforge, expedient, explicit, fashion, FCA, floating, foreseeable, friend, GDPR, GPO, Gynecology, harbor, Harmonization, HealthTrust, Hikma, Hospira, hosting, HRSA, hydromorphone, hypotension, hypotensive, indemnity, infusion, interlocutory, intradermal, Invanz, investigatory, lapse, lapsing, LTCI, Mendham, methylsulfate, milligram, minute, ml, moderate, moiety, narrative, necessitating, Nevakar, nichol, noncurrent, nystatin, Pfizer, pleading, PMPRB, protein, province, provincial, purified, QSF, recognizable, reconsider, recordkeeping, Reed, regular, rejoin, renegotiate, reply, resource, retaliatory, rulemaking, rupee, SAB, sBLA, scrutinize, Seller, shock, Shortly, slowdown, slower, Somerset, span, Stewardship, styled, sweeping, Takeda, tariff, transgression, unconditional, unconstitutional, undelivered, unfulfilled, unvested, USTR, VA, vasodilatory, vasostrict®, venue, Vintage, Vizient, waived, week, Wintac, zoledronic
Removed:
abused, accurate, acetaminophen, addiction, ADHD, affirmed, amend, AMP, assertion, attainment, Bernard, bridge, buspirone, Chancery, choose, CII, Clara, clarification, CMC, collectability, commodity, confirmed, consume, controlling, corrected, culminated, DAC, daniel, death, determinable, deterrent, diagnosing, diligent, distinguish, divided, economically, eliminate, entirety, equivalence, existed, factually, fluoxetine, frame, GlaxoSmithKline, GLP, GSK, Hampshire, hyperalgesia, inclusion, IND, Indiana, inter, interfere, intervened, investee, IRB, Jill, Lisitza, Louisiana, mandatorily, Maryland, Matched, Mexico, mg, natesto, neutral, noncontrolling, people, placement, posted, preclude, predominately, purport, qualitative, quantitative, questioned, ranitidine, rare, realigned, realigning, reallocation, reclassifying, reinvestment, relied, remand, repair, repatriated, requesting, retained, Room, rudio, Rye, Santa, Seroquel, Shire, simultaneously, Smith, Sobi, split, strategically, Street, superseded, supportable, tablet, Tennessee, tolerated, transparent, troubled, UEO, uncleared, unsealed, unused, upholding, USOPM, Utah, Watson, wrongfully, XR, Zetia
Filing tables
Filing exhibits
- 10-K Annual report
- 10.21 Exhibit 10.21 Pera Employment Agreement
- 14.1 Exhibit 14.1 Code of Conduct
- 21.1 Exhibit 21.1 12.31.2018 Subsidiaries
- 23.1 Exhibit 23.1 Consent of PWC
- 24.1 Exhibit 24.1 Power of Attorney
- 31.1 Exhibit 31.1 CEO 302 Cert
- 31.2 Exhibit 31.2 CFO 302 Cert
- 32.1 Exhibit 32.1 CEO 906 Cert
- 32.2 Exhibit 32.2 CFO 906 Cert
- Download Excel data file
- View Excel data file
Related press release
Associated ENDPQ transcripts
ENDPQ similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Blaise Coleman, as Chief Financial Officer of Endo International plc (the Company), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Annual Report on Form 10-K of the Company for the annual period ended December 31, 2018 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/S/ BLAISE COLEMAN | |||
Name: | Blaise Coleman | ||
Title: | Executive Vice President, Chief Financial Officer (Principal Financial Officer) |
Date: February 28, 2019
A signed original of this written statement required by Section 906 has been provided to, and will be retained by, Endo International plc and furnished to the Securities and Exchange Commission or its staff upon request.